New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension (original) (raw)

European respiratory review : an official journal of the European Respiratory Society, 2013

Abstract

The past two decades have seen significant improvements in the management of patients with pulmonary arterial hypertension (PAH). Although outcome has improved, long-term prognosis remains unsatisfactory. The development of new treatment options is clearly important. Equally important is testing new agents in trials designed to provide robust evidence for sustained clinical benefits enabling clinicians to determine the optimal treatment strategy for individual patients. End-points such as the change in 6-min walk distance (6MWD) have been pivotal in the registration trials of currently available PAH-specific therapies. However, as current clinical trials enrol patients with milder disease, many already on background therapy, there is growing evidence that change from baseline in 6MWD is a weak surrogate of outcome in PAH. In addition, while short-term trials allowed for the rapid approval of PAH therapies in the past, there is increasing recognition that clinical trials for new agen...

Ioana Preston hasn't uploaded this paper.

Let Ioana know you want this paper to be uploaded.

Ask for this paper to be uploaded.